Cancer is the second cause of death in the USA and Europe, and colorectal carcinoma is the second most prevalent malignancy in these continents. The availability of a tumour marker detectable in serum would be-helpful in confirming the diagnosis of colorectal carcinoma. Since its discovery (Gold & Freedman, 1965) , the use of carcinoembryonic antigen (CEA) as a tumour marker has become widespread. Unfortunately, CEA appeared to be neither organ-specific, nor tumour-specific (Bates & Longo, 1987) . Therefore, CEA is not very useful in the primary diagnosis of colorectal carcinoma, but it has proved to be an effective monitor for the follow-up of these cancers (Fletcher, 1986) .
The search for new serum tumour markers has favoured the development of monoclonal antibodies, which can be raised and directed against circulating tumour-associated antigens (TAA). The carbohydrate antigen 19-9 (CA 19-9) has been described as potentially useful in the diagnosis of colorectal carcinoma (Koprowski et al., 1979; Herlyn et al., 1982) . One year later, the carbohydrate antigen 50 (CA 50) was recognised (Lindholm et al., 1983) as a promising diagnostic marker for cancers of colon and rectum. The monoclonal antibodies (MAbs) used in the test kits of CA19-9 have been shown to react with sialylated Lacto N-fucopentose II (sialyl-Lea), a circulating epitope of the Lewis blood group antigen . The MAbs reactive with the TAA CA 50 react with two different carbohydrate structures, sialyl-Lea and sialosyl-lactotetraose (Nilsson et al., 1985) . More recently, the TAA 195 (CA 195) was described (Bray et al., 1987) . The MAbs recognising CA 195 have been shown to react with both Lea and sialyl-Lea epitopes (Fukuta et al., 1987) . In the case of CA 50 it was reported that it might be tumour-specific (Holmgren et al., 1984) , whereas CA 19-9 and CA 195 might be organ-specific (Bhargava et al., 1987; Sundaram et al., 1987) . In comparison with CA 195 seems to be less often elevated in benign disease, i.e., it might be more specific for malignancies than CA 19-9 (Bhargava et al., 1989) .
It has been reported that individuals with the Lewisa-bphenotype cannot synthesise CA 19-9, because they lack the necessary fucosyltransferase enzyme Magnani et al., 1983) . In these individuals, CA 19-9 cannot be used for the detection of colorectal cancers. The same applies to CA 50 and CA 195, the production of which also depends on the enzyme fucosyltransferase. The lack of fucosyltransferase concerns approximately 10% of the general population (Watkins, 1980 (Astler & Coller, 1954 , 1992) . The precision of the assays was calculated for the means of duplicate determinations of several different serum pools in terms of within-assay and between-assay coefficients of variation (CVW and CVb, respectively) as described by Rodbard (1974) . The CV,'s ranged from 2.0% (CA 50) to 5.1% (CEA), whereas the CVb's ranged between 6.2% (CA 195) and 11.7% (CA 50).
Statistical methods
The usefulness of the serum markers for the primary diagnosis of colorectal carcinoma was assessed by cumulative frequency distributions and Receiver Operating Characteristic (ROC) curves. The cumulative frequency distributions display the cumulative percentage of colorectal cancer patients as well as of patients with benign colorectal disorders against the serum marker concentration. The resulting figures allow the reading of sensitivity and specificity at any requested cut-off level for test positivity. Furthermore, it shows the extent of overlap of the marker distribution of carcinoma patients with that of the patients with benign disorders. ROC curves plot the sensitivity against one minus specificity at various cut-off levels of the diagnostic test. A non-discriminating test will have an ROC curve which coincides with the diagonal. A perfect test will have an ROC curve in the upper left corner of the diagram (Metz, 1978; Swets, 1973; Weinstein & Feinberg, 1980) . The area under the curve (AUC), ranging from 0.5 for a non-discriminating test to 1.0 for a perfect test, is a measure for the diagnostic ability of a test (Hanley & McNeil, 1982) .
The usefulness of combinations of markers was assessed by ROC curves as well. Combinations of the markers were made by adding and multiplying, respectively, the concentrations of markers for individual patients.
The prognostic value of the markers with respect to first recurrence of disease was assessed by fitting a Cox' proportional hazards model for each marker, with time from surgery to first recurrence of disease in months as the dependent variable (Cox, 1972) . Tumour-free status at the end of the study and death were considered censored. Table I shows the median and maximum serum concentrations of the four individual tumour markers for carcinoma patients for the different stages of disease. Means are not presented, due to the skew distributions of the four markers.
Results
To improve the clarity of the Tables, minimum levels of marker concentration are not displayed either. These minima approximate the lowest detectable concentration for all disease stages, locations and grades of differentiation and no increasing trend could be observed in the minima. Maximum concentrations of CEA, CA 19-9 CA 50 and CA 195 increase with increasing extent of Eisease. In the case of median levels this trend cannot be observed; they are approximately similar in all stages of disease, except for 'Dukes' D' ( Table I) these tumours, which were all 'Dukes' D'. Apparently, in clinical practice the grade of differentiation is frequently not established in patients with distant metastases. Table II presents median and maximum observed concentrations of the markers in patients with benign colorectal disorders. It is noted that the maximum concentration for all markers is found in patients with diverticular disease.
Figures 1 through 4 display the cumulative frequency distributions for the markers. They present a rather similar picture; the distribution of the carcinoma patients shows an 80-90% overlap with that of the benign colorectal disorder patients, but for all markers a cut-off point can be determined above which patients almost certainly have carcinomas. This point is indicated in each figure and varies from 18 ng ml-' for CEA to 340 arbitrary U ml-', 140 arbitrary U ml-' and 58arbitraryUml' for CA 19-9, CA 50, and CA 195, respectively. Figure 5 presents the ROC curves and the corresponding li slightly better, having an AUC of 0.70 (95% Cl 0.63-0.77), which, however, is not statistically significant. Organspecificity was not investigated in the present study, but the tumour-specificity is disappointing. Even CA 50, which has been reported to be tumour-specific (Holmgren et al., 1984) does not show a better discriminative ability than CEA, which is known to be increased in nonmalignant disorders and healthy smokers (Moore et al., 1989) (Fukuta et al., 1987) . This is not confirmed by the present study. CA 19-9 and CA 50 have been reported to show identical diagnostic results (Roberts, 1988) , although CA 50 reacts with an epitope also containing sialosyl-lactotetraose (Nilsson et al., 1985) . These findings are in accordance with our data.
Combinations of the four markers did not improve diagnostic performance significantly, as is clear from Figure 6 . This was to be expected from the high correlation between the markers. Apparently, there is still discussion on the diagnostic value of combinations of markers. Some authors report improved diagnostic power for a combination markers, others report approximately equal diagnostic power (Kuusela et al., 1984; Bray & Gaur, 1988; Bhargava et al., 1989) .
Probably, the poor diagnostic power of all three new markers can at least partly be explained by the lack of the enzyme fucosyltransferase in approximately 10% of the population (Watkins, 1980) , who have a Lea4b phenotype and hence cannot synthesise CA 19-9, CA 50 and CA 195 (Koprowski et al., 1982; Magnani et al., 1983) . Recently it was suggested that the Leab phenotype is more frequent in patients with urinary bladder (12.2%) and colorectal (23.8%) carcinoma (Langkilde et al., 1991) . However, in this study the Lewis phenotypes were determined on the erythrocytes, and it has been demonstrated that their phenotype can convert from Lewis-positive to Lewis-negative (Hirano et al., 1987) . Therefore, as far as studies based on Lewis phenotype determination are concerned, the hypothesis is yet to be investigated in serum, which does not allow conversion (Hirano et al., 1987) and on tumour tissue. Only CEA has some relationship with the extent of the disease, as can be concluded from the higher CEA concentrations in patients with more extensive disease. Therefore, unlike CEA, the markers CA 19-9, CA 50 and CA 195 are probably neither useful for the primary diagnosis nor for the staging of colorectal carcinoma. Although they were developed from colorectal cell lines (Koprowski et al., 1979; Schwartz, 1990) , there are indications that some of these markers could play a role in the diagnosis of pancreatic cancer (Staab et al., 1985; Paganuzzi et al., 1988; Bhargava et al., 1988) . In the case of CA 19-9 a sensitivity of 89% is reported at a specificity level of 95% (Staab et al., 1985) , whereas a sensitivity of 81% at a specificity of 89% is described for CA 50 (Paganuzzi et al., 1988 ) and a sensitivity of 64% at a specificity of 94% for CA 195 (Bhargava et al., 1988) .
Our data show that none of the tumour markers had prognostic value, that is, none of the markers could predict recurrence of disease within 34 months after diagnosis (median follow-up, maximum follow-up is 81 months).
The three new markers were evaluated in accordance with a so-called first phase of diagnostic marker assessment as was described recently (Van der Schouw et al., submitted) . In that paper it was indicated that the spectrum of participating patients must represent the spectrum of patients that is seen in clinical practice. The colorectal cancer patients as well as the benign colorectal disease patients in the present paper are a representation of the patients presenting to the out-patient Department of General Surgery of a university hospital. The promising diagnostic power of the serum tumour markers as described in literature probably results from comparisons of serum marker concentrations of colorectal cancer patients with those of healthy individuals and patients with noncolorectal benign disorders (Holmgren et al., 1984; Bhargava et al., 1987) .
The methods of statistical analysis used in this paper are also put forward in those recently proposed guidelines (Van der Schouw et al., submitted) . They form a convenient way of expressing the diagnostic power of a test, mainly because they are independent of cut-off levels for test positivity. Such an analysis shows sensitivities and specificities at all possible cut-off points simultaneously. Cumulative frequency distributions show the relationship of these test characteristics for the particular serum marker concentrations. Finally, ROC curves provide one summary measure of performance, i.e. the AUC, rather than two separate measures, i.e. sensitivity and specificity, which have to be considered simultaneously. Furthermore, ROC curves provide the possibility of comparing multiple tests of which the results are expressed on different scales, such as ng ml-' or arbitrary U ml-' as is the case in the present paper.
It can be concluded that CA 19-9, CA 50 and CA 195 do not appear to be very useful in the primary diagnosis of colorectal carcinoma. Probably, they are not of value in staging the disease and in prognosis either. Investigation into the value of the markers in the monitoring of colorectal carcinoma and the diagnosis, staging and monitoring of pancreatic carcinoma is necessary and, indeed, in progress.
